DXCM

$82.292.95%2.36

시간 외 거래: 83.50+1.21 +1.47%

Dexcom Inc (DXCM)

Date: O: H: L: C: Vol:

전일 마감가:

$79.93

열려 있는:

$81.52

하루 거래량:

8,629,700

상대 거래량:

1.44

시가총액:

$31.05B

수익:

$4.82B

순이익/손실:

$930.40M

주가수익비율:

35.20

EPS:

$2.34

순현금흐름:

$1.43B

1W 성능:

+5.58%

1M 성능:

-4.64%

6M 성능:

+38.19%

1Y 성능:

+20.66%

1일 변동 폭

$79.79$85.25

1주일 범위

$76.52$85.25

52주 변동 폭

$54.11$92.59

Dexcom Inc 주식 (DXCM) 회사 개요

명칭

Dexcom Inc

부문

Healthcare

산업

Medical Devices

전화

(858) 200-0200

주소

6340 SEQUENCE DRIVE, SAN DIEGO, CA, USA

직원

11,100

@dexcom

다음 수익 날짜

null

최신 SEC 제출 서류

SEC

X에서 DXCM에 대한 토론

DXCM vs ABT, MDT, SYK, BSX, EW 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
DXCM Dexcom Inc	$82.29	$31.05B	$4.82B	$930.40M	$1.43B	$2.34
ABT Abbott Laboratories	$106.20	$183.77B	$46.59B	$5.41B	$7.38B	$3.09
MDT Medtronic Plc	$96.54	$123.49B	$36.36B	$4.84B	$5.43B	$3.73
SYK Stryker Corp	$291.86	$111.95B	$25.27B	$3.34B	$4.57B	$8.63
BSX Boston Scientific Corp	$41.98	$60.84B	$20.62B	$3.56B	$3.48B	$2.38
EW Edwards Lifesciences Corp	$92.01	$53.03B	$6.30B	$1.07B	$1.09B	$1.84

Dexcom Inc 주식(DXCM) 업그레이드 및 다운그레이드

날짜	액션	분석자	등급 변경
2026-10-07	개시	Barclays	Overweight
2026-06-23	개시	Deutsche Bank	Buy
2026-05-12	개시	The Benchmark Company	Buy
2026-03-24	업그레이드	Evercore ISI	In-line → Outperform
2026-01-12	다운그레이드	Barclays	Equal Weight → Underweight
2025-12-02	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2025-11-25	개시	Evercore ISI	In-line
2025-10-21	Resumed	Stifel	Buy
2025-09-08	다운그레이드	Oppenheimer	Outperform → Perform
2025-08-21	개시	Argus	Buy
2025-06-16	개시	Truist	Buy
2025-05-30	개시	Goldman	Buy
2025-04-10	개시	Mizuho	Outperform
2025-02-03	업그레이드	Redburn Atlantic	Neutral → Buy
2025-01-16	업그레이드	Robert W. Baird	Neutral → Outperform
2024-07-26	다운그레이드	JP Morgan	Overweight → Neutral
2024-07-26	다운그레이드	Robert W. Baird	Outperform → Neutral
2024-05-30	개시	Redburn Atlantic	Neutral
2024-03-12	개시	RBC Capital Mkts	Outperform
2023-05-30	Resumed	Morgan Stanley	Equal-Weight
2023-04-17	업그레이드	Raymond James	Outperform → Strong Buy
2023-03-29	개시	UBS	Buy
2023-01-26	개시	Wolfe Research	Outperform
2022-10-18	개시	Barclays	Equal Weight
2022-10-12	개시	Jefferies	Buy
2022-07-15	개시	Bernstein	Outperform
2022-03-02	Resumed	BofA Securities	Buy
2022-02-03	업그레이드	BTIG Research	Neutral → Buy
2022-01-19	업그레이드	Wells Fargo	Equal Weight → Overweight
2022-01-07	업그레이드	Guggenheim	Neutral → Buy
2021-10-18	다운그레이드	Guggenheim	Buy → Neutral
2021-07-21	Resumed	Cowen	Outperform
2021-05-28	업그레이드	Wells Fargo	Underweight → Equal Weight
2021-05-25	개시	Barclays	Overweight
2021-04-15	개시	Atlantic Equities	Overweight
2021-01-06	업그레이드	UBS	Neutral → Buy
2020-10-02	다운그레이드	Wells Fargo	Equal Weight → Underweight
2020-05-27	재확인	Piper Sandler	Overweight
2020-05-14	개시	Wells Fargo	Equal Weight
2020-03-05	개시	Citigroup	Buy
2019-11-07	재확인	Canaccord Genuity	Buy
2019-11-07	업그레이드	Guggenheim	Neutral → Buy
2019-10-23	개시	Stifel	Buy
2018-11-28	개시	UBS	Neutral
2018-10-19	업그레이드	Goldman	Sell → Neutral
2018-09-12	업그레이드	Northland Capital	Under Perform → Market Perform
2018-08-02	재확인	Canaccord Genuity	Buy
2018-07-02	업그레이드	Raymond James	Mkt Perform → Outperform
2018-06-08	업그레이드	JP Morgan	Neutral → Overweight
2018-05-11	개시	BofA/Merrill	Buy
2018-05-03	재확인	Canaccord Genuity	Buy
2018-04-04	개시	Goldman	Sell
2018-04-04	개시	Guggenheim	Neutral
2018-03-23	업그레이드	Robert W. Baird	Neutral → Outperform
2018-01-04	다운그레이드	Northland Capital	Market Perform → Under Perform
2017-09-28	재확인	Wedbush	Outperform

Dexcom Inc (DXCM) 재무 분석

매출

순이익

현금흐름

주당 순 이익

Dexcom Inc 주식 (DXCM) 내부자 거래

SADIE STERNOct 27 '26
Officer
거래
Proposed Sale
비용
$78.62
#주식
2,565
가치 ($)
201,660
#주식 총계
0
MICHAEL BROWNOct 15 '26
Officer
거래
Proposed Sale
비용
$85.48
#주식
1,700
가치 ($)
145,316
#주식 총계
0
Brown Michael JonOct 15 '26
EVP Chief Legal Compliance Off
거래
Sale
비용
$85.48
#주식
1,700
가치 ($)
145,316
#주식 총계
98,185
Stern SadieSep 28 '26
EVP Chief People & Culture Off
거래
Sale
비용
$86.15
#주식
2,565
가치 ($)
220,975
#주식 총계
123,478
SADIE STERNSep 28 '26
Officer
거래
Proposed Sale
비용
$86.15
#주식
2,565
가치 ($)
220,975
#주식 총계
0
Brown Michael JonSep 15 '26
EVP Chief Legal Compliance Off
거래
Sale
비용
$84.04
#주식
1,700
가치 ($)
142,868
#주식 총계
99,885
AUGUSTINOS NICHOLASSep 15 '26
Director
거래
Sale
비용
$84.04
#주식
6,539
가치 ($)
549,538
#주식 총계
29,293
AUGUSTINOS NICHOLASSep 15 '26
Director
거래
Proposed Sale
비용
$84.04
#주식
6,539
가치 ($)
549,538
#주식 총계
0
MICHAEL BROWNSep 15 '26
Officer
거래
Proposed Sale
비용
$84.04
#주식
1,700
가치 ($)
142,868
#주식 총계
0
AUGUSTINOS NICHOLASSep 14 '26
Director
거래
Proposed Sale
비용
$84.02
#주식
1,550
가치 ($)
130,231
#주식 총계
0

내부자 거래	관계	날짜	거래	비용	#주식	가치 ($)	#주식 총계
SADIE STERN	Officer	Oct 27 '26	Proposed Sale	$78.62	2,565	201,660	0
MICHAEL BROWN	Officer	Oct 15 '26	Proposed Sale	$85.48	1,700	145,316	0
Brown Michael Jon	EVP Chief Legal Compliance Off	Oct 15 '26	Sale	$85.48	1,700	145,316	98,185
Stern Sadie	EVP Chief People & Culture Off	Sep 28 '26	Sale	$86.15	2,565	220,975	123,478
SADIE STERN	Officer	Sep 28 '26	Proposed Sale	$86.15	2,565	220,975	0
Brown Michael Jon	EVP Chief Legal Compliance Off	Sep 15 '26	Sale	$84.04	1,700	142,868	99,885
AUGUSTINOS NICHOLAS	Director	Sep 15 '26	Sale	$84.04	6,539	549,538	29,293
AUGUSTINOS NICHOLAS	Director	Sep 15 '26	Proposed Sale	$84.04	6,539	549,538	0
MICHAEL BROWN	Officer	Sep 15 '26	Proposed Sale	$84.04	1,700	142,868	0
AUGUSTINOS NICHOLAS	Director	Sep 14 '26	Proposed Sale	$84.02	1,550	130,231	0

Dexcom Inc 주식(DXCM)의 최신 뉴스

Oct 30, 2026

DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise - Zacks Investment Research

Oct 30, 2026

Oct 28, 2026

DexCom (DXCM) to Launch Dexcom G7 15 Day CGM System in Canada Ne - GuruFocus

Oct 28, 2026

Dexcom launches 15-day glucose monitor in Canada next month By Investing.com - Investing.com India

Oct 28, 2026

Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November - DexCom, Inc. - Investor Relations

Oct 28, 2026

Dexcom G7 15 Day glucose monitor to launch in Canada in November - StreetInsider

Oct 28, 2026

What to expect from DexCom’s (DXCM) Q3 earnings - Yahoo Finance

Oct 28, 2026

Oct 27, 2026

Here’s How Much You Would Have Made Owning DexCom Stock In The Last 15 Years - Benzinga

Oct 27, 2026

Our Dexcom Pick Had a Minor Setback. It’s Still a Diabetes Winner. - Barron's

Oct 27, 2026

Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire

Oct 27, 2026

Oct 26, 2026

Is DexCom (DXCM) Cheap After CONNECT Trial Results Backed G7 Adoption? - Simply Wall Street

Oct 26, 2026

DexCom Gears Up to Report Q3 Results: How to Play the Stock? - Zacks Investment Research

Oct 26, 2026

DexCom Gears Up to Report Q3 Results: How to Play the Stock? - Zacks Investment Research

Oct 26, 2026

DexCom Gears Up to Report Q3 Results: How to Play the Stock? - TradingView

Oct 26, 2026

Leerink Partners Adjusts Price Target on DexCom to $87 From $94 - marketscreener.com

Oct 26, 2026

DexCom Inc (DXCM) Shares Fall 6.4% -- What GF Score of 95 Tells Investors - GuruFocus

Oct 21, 2026

Precision Trading with Dexcom Inc. (DXCM) Risk Zones - Stock Traders Daily

Oct 21, 2026

DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Oct 21, 2026

DexCom (DXCM) Shares Fall 6.5% Amid Broader Market Gains on Octo - GuruFocus

Oct 21, 2026

S&P 500 Top Movers on Oct. 21, 2026: Supermicro Leads Gainers, Dexcom Leads Losers - ChartMill

Oct 21, 2026

Global Digital Health and Remote Patient Monitoring Strategic Market Report, 2026-2031 | 20.2% CAGR to $80.8 Billion as Connected Care and Wearables Scale - GlobeNewswire Inc.

Oct 21, 2026

Oct 20, 2026

DexCom Inc. Company & People | DXCM.USD - Barron's

Oct 20, 2026

DXCM.USD | DexCom Inc. Stock Overview (Switzerland: SWX) - Barron's

Oct 20, 2026

DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study - Zacks Investment Research

Oct 20, 2026

DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study - Yahoo! Finance Canada

Oct 20, 2026

Oct 19, 2026

Form 4 DexCom Inc: Michael Jon Brown (EVP Chief Legal Compliance Off) For: 15 October By Investing.com - Investing.com South Africa

Oct 19, 2026

Dexcom EVP Michael Brown sells $145,316 in company stock - Investing.com

Oct 19, 2026

Oct 18, 2026

Dexcom class action lawsuits claim ShinyHunters stole health data - Top Class Actions

Oct 18, 2026

Oct 17, 2026

DexCom: The 15-Day Sensor Lowered The Cost Curve Before The Type 2 Wave Arrives - Seeking Alpha

Oct 17, 2026

Oct 16, 2026

DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch

Oct 16, 2026

DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch

Oct 16, 2026

Dexcom faces a class action over an alleged data breach that ShinyHunters claimed responsibility for. - Claim Depot

Oct 16, 2026

Vaso Stock Surges 149% in a Year: What's Behind the Rally? - TradingView

Oct 16, 2026

Vaso Stock Surges 149% in a Year: What's Behind the Rally? - Zacks Investment Research

Oct 16, 2026

Oct 15, 2026

A Look at DexCom Inc (DXCM) After 5.1% Gain -- GF Value $103.59 vs Price $87.71 - GuruFocus

Oct 15, 2026

DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 15, 2026

DexCom gains as NEJM publication boosts Medicare coverage hopes - TradingView

Oct 15, 2026

Oct 14, 2026

Landmark Dexcom CONNECT Study Published in The New England Journ - GuruFocus

Oct 14, 2026

Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin - Dexcom

Oct 14, 2026

Oct 13, 2026

DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Oct 13, 2026

DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Oct 13, 2026

Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - Zacks Investment Research

Oct 13, 2026

Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - Yahoo Finance

Oct 13, 2026

DexCom (NASDAQ:DXCM): Affordable Growth at a Reasonable Valuation - ChartMill

Oct 13, 2026

Here's What to Expect From DexCom’s Next Earnings Report - inkl

Oct 13, 2026

Here's What to Expect From DexCom’s Next Earnings Report - Yahoo Finance

Oct 13, 2026

DXCM와(과) 유사한 종목

Dexcom Inc (DXCM)

Dexcom Inc 주식 (DXCM) 회사 개요

DXCM vs ABT, MDT, SYK, BSX, EW 비교

Dexcom Inc 주식(DXCM) 업그레이드 및 다운그레이드

Dexcom Inc (DXCM) 재무 분석

매출

순이익

현금흐름

주당 순 이익

Dexcom Inc 주식 (DXCM) 내부자 거래

Dexcom Inc 주식(DXCM)의 최신 뉴스

DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise - Zacks Investment Research

DexCom (DXCM) to Launch Dexcom G7 15 Day CGM System in Canada Ne - GuruFocus

Dexcom launches 15-day glucose monitor in Canada next month By Investing.com - Investing.com India

Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November - DexCom, Inc. - Investor Relations

Dexcom G7 15 Day glucose monitor to launch in Canada in November - StreetInsider

What to expect from DexCom’s (DXCM) Q3 earnings - Yahoo Finance

Here’s How Much You Would Have Made Owning DexCom Stock In The Last 15 Years - Benzinga

Our Dexcom Pick Had a Minor Setback. It’s Still a Diabetes Winner. - Barron's

Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire

Is DexCom (DXCM) Cheap After CONNECT Trial Results Backed G7 Adoption? - Simply Wall Street

DexCom Gears Up to Report Q3 Results: How to Play the Stock? - Zacks Investment Research

DexCom Gears Up to Report Q3 Results: How to Play the Stock? - Zacks Investment Research

DexCom Gears Up to Report Q3 Results: How to Play the Stock? - TradingView

Leerink Partners Adjusts Price Target on DexCom to $87 From $94 - marketscreener.com

Dexcom Inc Lobbying Profile, 2020 - OpenSecrets

Form 144 DEXCOM For: 26 October By Investing.com - Investing.com Nigeria

DexCom, Inc. (DXCM) Options Chain - Yahoo Finance - Yahoo! Finance Canada

DexCom, Inc. Estimates – NASDAQ:DXCM - TradingView

Why Is DexCom (DXCM) In Focus After Its G7 Trial Reached NEJM? - Yahoo Finance

DexCom Inc (DXCM) Shares Fall 6.4% -- What GF Score of 95 Tells Investors - GuruFocus

Precision Trading with Dexcom Inc. (DXCM) Risk Zones - Stock Traders Daily

DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

DexCom (DXCM) Shares Fall 6.5% Amid Broader Market Gains on Octo - GuruFocus

S&P 500 Top Movers on Oct. 21, 2026: Supermicro Leads Gainers, Dexcom Leads Losers - ChartMill

Global Digital Health and Remote Patient Monitoring Strategic Market Report, 2026-2031 | 20.2% CAGR to $80.8 Billion as Connected Care and Wearables Scale - GlobeNewswire Inc.

DexCom Inc. Company & People | DXCM.USD - Barron's

DXCM.USD | DexCom Inc. Stock Overview (Switzerland: SWX) - Barron's

DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study - Zacks Investment Research

DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study - Yahoo! Finance Canada

Form 4 DexCom Inc: Michael Jon Brown (EVP Chief Legal Compliance Off) For: 15 October By Investing.com - Investing.com South Africa

Dexcom EVP Michael Brown sells $145,316 in company stock - Investing.com

Dexcom class action lawsuits claim ShinyHunters stole health data - Top Class Actions

DexCom: The 15-Day Sensor Lowered The Cost Curve Before The Type 2 Wave Arrives - Seeking Alpha

DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch

DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch

Dexcom faces a class action over an alleged data breach that ShinyHunters claimed responsibility for. - Claim Depot

Vaso Stock Surges 149% in a Year: What's Behind the Rally? - TradingView

Vaso Stock Surges 149% in a Year: What's Behind the Rally? - Zacks Investment Research

A Look at DexCom Inc (DXCM) After 5.1% Gain -- GF Value $103.59 vs Price $87.71 - GuruFocus

DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch

DexCom gains as NEJM publication boosts Medicare coverage hopes - TradingView

Landmark Dexcom CONNECT Study Published in The New England Journ - GuruFocus

Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin - Dexcom

DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - Zacks Investment Research

Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - Yahoo Finance

DexCom (NASDAQ:DXCM): Affordable Growth at a Reasonable Valuation - ChartMill

Here's What to Expect From DexCom’s Next Earnings Report - inkl

Here's What to Expect From DexCom’s Next Earnings Report - Yahoo Finance

DXCM와(과) 유사한 종목